Edwin Kania
CIK 1255927 · last filed 2026-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MCRB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
800 BOYLSTON STREET
BOSTON, MA 02199
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TMDX | Director | 309,874 | $72.75 | $22.54M | $2.79M | 12 | 2026-05-22 |
| MRNA | 10%+ Owner | 23,847 | $258.38 | $6.16M | -$11.50M | 2 | 2020-01-14 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 586,595 | $0.88 | $516.9K | -$3.74M | 2 | 2017-05-16 |
| Carisma Therapeutics Inc. (EBIO) Delisted | 10%+ Owner | 1,833,802 | — | — | -$195.1K | 1 | 2016-09-16 |
| MCRB | 10%+ Owner | 0 | $2.09 | $0 | -$27.60M | 1 | 2016-05-27 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 529,154 | $178.75 | $94.59M | -$2.07M | 6 | 2015-04-08 |
| BG Medicine, Inc. (BGMD) Delisted | 10%+ Owner | 92,278 | — | — | -$201.1K | 3 | 2014-12-11 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 10%+ Owner | 563,482 | $8.37 | $4.72M | $0 | 1 | 2014-02-19 |
| DNIB UNWIND, INC. (BIND) Delisted | 10%+ Owner | 1,542,616 | — | — | $300.0K | 1 | 2013-09-27 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 1,375,290 | $104.91 | $144.28M | $0 | 4 | 2009-07-21 |
Recent Filings · Page 2 of 4
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-12 | TMDX | Other (J) | −386,127 | $0 | EDGAR |
| 2019-12-11 | MRNA | Sell (S) | −100,000 | -$1.88M | EDGAR |
| 2019-10-31 | TMDX | Other (J) | +120,595 | $0 | EDGAR |
| 2019-05-06 | TMDX | Mixed | −12,625 | $533.3K | EDGAR |
| 2017-05-16 | Cartesian Therapeutics, Inc. (SELB) Delisted | Sell (S) | −266,795 | -$3.74M | EDGAR |
| 2016-09-16 | Carisma Therapeutics Inc. (EBIO) Delisted | Sell (S) | −46,692 | -$195.1K | EDGAR |
| 2016-06-29 | Cartesian Therapeutics, Inc. (SELB) Delisted | Conv (C) | +1,620,747 | $0 | EDGAR |
| 2016-05-27 | MCRB | Mixed | −2,000,000 | -$27.60M | EDGAR |
| 2015-04-08 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-01-09 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.